



## **AgiOS Announces New Commercial Leadership Structure**

April 2, 2019

*Darrin Miles Appointed Senior Vice President, U.S. Commercial & Global Marketing; Previously Served as Vice President, Oncology Program Leadership at Agios*

*Search Initiated for Senior Vice President, International to Lead the Build-Out of European Operations, Rest-of-World Strategy and Potential EU Launch of TIBSOVO®*

CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced two newly created commercial leadership roles to support the commercialization of the company's medicines in the United States and Europe. Darrin Miles, who has been with the company since 2015, most recently as vice president, oncology program leadership, has been promoted to senior vice president, U.S. commercial and global marketing and will be responsible for leading the commercial organization in the U.S. and driving coordinated marketing efforts worldwide for all of Agios products and development candidates. In addition, a search is underway for the role of senior vice president, international, who will be responsible for building and leading the company's operations outside of the U.S. in support of the potential launch of TIBSOVO® in Europe and potentially other select markets. Both will report to Jackie Fouse, Ph.D., chief executive officer at Agios.

"It's an incredibly exciting time for Agios as we continue to execute on the U.S. launch of our first wholly owned medicine and prepare for our first approval in the EU. We believe this new leadership structure will provide the greatest possible expertise and focus for our team across both geographies," said Dr. Fouse. "Darrin has been instrumental in the strategy and success of the IDH franchise to date, and we are confident that his new role, working closely with the newly established international role, will maximize the full value potential of TIBSOVO® for patients worldwide and position us well for future expected launches across our oncology and rare genetic disease programs."

Mr. Miles has more than 20 years of experience across a range of commercial and program management roles in pharmaceuticals and biotechnology. He joined Agios in 2015 as vice president, oncology marketing and market analytics and most recently served as vice president, oncology program leadership, where he has been instrumental in setting the strategy for the IDH portfolio and leading the program team through the development and approval of TIBSOVO®. Prior to joining Agios, Mr. Miles spent 14 years at Genentech, where he held roles of increasing responsibility including marketing, sales management, reimbursement and lifecycle leadership supporting a broad portfolio of brands including Rituxan®, Herceptin®, Tarceva® and Lucentis®. He also led the U.S. launches of next generation anti-HER2 treatments Perjeta® and Kadcyca®. Prior to Genentech, Mr. Miles spent a number of years at ALZA Corporation and SmithKline Beecham (now GSK) in numerous roles including marketing, market analytics and organization development. Mr. Miles holds a B.S. in applied economics with a minor in biological sciences from Cornell University.

### **About Agios**

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at [www.agios.com](http://www.agios.com).

### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected benefits of Mr. Miles's employment and Agios' strategic plans and focus. The words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, that development of any of Agios' product candidates will successfully continue, or that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

### **Investor & Media Contact**

Holly Manning, 617-844-6630  
Associate Director, Investor Relations  
[Holly.Manning@agios.com](mailto:Holly.Manning@agios.com)



Source: Agios Pharmaceuticals, Inc.